vs
Side-by-side financial comparison of AbbVie (ABBV) and MAINZ BIOMED N.V. (MYNZ). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $214.8K, roughly 77379.0× MAINZ BIOMED N.V.).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Mainz Biomed N.V. is a molecular diagnostics company specializing in the development and commercialization of non-invasive early detection tests for gastrointestinal cancers, primarily colorectal cancer. Its flagship product ColoAlert is approved and available across European markets, with active expansion initiatives targeting North America and other global regions.
ABBV vs MYNZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $214.8K |
| Net Profit | $1.8B | — |
| Gross Margin | 72.6% | 62.7% |
| Operating Margin | 27.3% | — |
| Net Margin | 10.9% | — |
| Revenue YoY | 10.0% | — |
| Net Profit YoY | 8354.5% | — |
| EPS (diluted) | $1.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | — | ||
| Q3 25 | $15.8B | — | ||
| Q2 25 | $15.4B | — | ||
| Q1 25 | $13.3B | — | ||
| Q4 24 | $15.1B | — | ||
| Q3 24 | $14.5B | — | ||
| Q2 24 | $14.5B | — | ||
| Q1 24 | $12.3B | — |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | — | ||
| Q2 25 | $938.0M | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $-22.0M | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | -9.9% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 27.6% | — | ||
| Q1 24 | 22.7% | — |
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 9.5% | — | ||
| Q1 24 | 11.1% | — |
| Q4 25 | $1.02 | — | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $0.52 | — | ||
| Q1 25 | $0.72 | — | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $0.88 | — | ||
| Q2 24 | $0.77 | — | ||
| Q1 24 | $0.77 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $7.1M |
| Total DebtLower is stronger | $58.9B | — |
| Stockholders' EquityBook value | $-3.3B | $3.4M |
| Total Assets | $134.0B | $15.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.7B | — | ||
| Q2 25 | $6.5B | — | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $5.6B | — | ||
| Q3 24 | $7.3B | — | ||
| Q2 24 | $13.2B | — | ||
| Q1 24 | $18.1B | — |
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
| Q4 25 | $-3.3B | — | ||
| Q3 25 | $-2.6B | — | ||
| Q2 25 | $-183.0M | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $6.0B | — | ||
| Q2 24 | $6.8B | — | ||
| Q1 24 | $8.0B | — |
| Q4 25 | $134.0B | — | ||
| Q3 25 | $133.9B | — | ||
| Q2 25 | $137.2B | — | ||
| Q1 25 | $136.2B | — | ||
| Q4 24 | $135.2B | — | ||
| Q3 24 | $143.4B | — | ||
| Q2 24 | $141.9B | — | ||
| Q1 24 | $148.9B | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | $-21.9M |
| Free Cash FlowOCF − Capex | $4.9B | — |
| FCF MarginFCF / Revenue | 29.4% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | 2.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $5.2B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $4.0B | — |
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $3.8B | — |
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 31.3% | — |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
